PLX
Protalix BioTherapeutics, Inc. Common Stock
Healthcare •
Biotechnology •
stocks •
XASE
• usd
$2.90
+$0.17
(+6.23%)
Loading...
SMA 20: -
SMA 50: -
SMA 200: -
| General | Valuation | Profitability | Financial Health | Trading | Ownership |
|---|---|---|---|---|---|
| Market Cap | $233.22M | EPS (ttm) | $0.08 | Current Price | $2.90 |
| Enterprise Value | $212.03M | Forward EPS | $0.62 | Previous Close | $2.73 |
| P/E Ratio | 36.25 | ROA | 5.53% | 52W High | $3.10 |
| Forward P/E | 4.68 | ROE | 12.64% | 52W Low | $1.32 |
| PEG Ratio | - | Gross Margin | 57.54% | 50 Day Avg | $1.90 |
| P/S Ratio | 3.77 | Operating Margin | 11.94% | 200 Day Avg | $1.89 |
| P/B Ratio | 4.40 | Profit Margin | 8.72% | Volume | 2.58M |
| EV/EBITDA | 27.26 | Current Ratio | 3.03 | Avg Volume | 769.42K |
| EV/Sales | 3.43 | Quick Ratio | 2.00 | Beta | -0.22 |
| Employees | 213.00 | Debt/Equity | 15.46 | Shares Outstanding | 80.42M |
| Sector | Healthcare | Total Debt | $8.18M | Float Shares | 71.93M |
| Industry | Biotechnology | Total Cash | $29.37M | Short Float | 5.90% |
| Optionable | Yes | Cash/Share | $0.36 | Short Ratio | 5.66 |
| Dividend Yield | - | Book Value/Share | $0.66 | % Held by Insiders | 10.15% |
| Target Price | $11.00 | Revenue (TTM) | $61.84M | % Held by Institutions | 17.91% |